Skip to main content

Advertisement

Log in

Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Tumor necrosis factor-alpha (TNFα) plays a central role in rheumatoid arthritis (RA) pathogenesis. There are cur-rently three available anti-TNFα agents for the treatment of RA—adalimumab, etanercept, and infliximab. These tar-geted therapies have select advantages over traditional disease-modifying antirheumatic drugs (DMARDs), agents that have long been the mainstay of RA treatment. Compared with conventional DMARDs, TNFα inhibitors display a rapid onset of action and have shown a significant effect in retarding the radiographic joint destruction that often char-acterizes RA disease progression. Although anti-TNFα drugs represent an important advance in RA treatment, postmarketing reports of serious infections, as well as other adverse events, highlight the need for continued postmarketing vigilance with the use of these agents. This review evaluates the unique attributes of the available TNFα inhibitors, focusing specifically on recent reports providing important insight into the understanding of drug-related efficacy and toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Shingu M, Nagai Y, Isayama T, et al.: The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase pro-duction by human chondrocytes and TIMP production by synovial cells and enothelial cells. Clin Exp Immunol 1993, 94:145–149.

    Article  PubMed  CAS  Google Scholar 

  2. Moser R, Schleiffenbaum B, Groscurth P, Fehr J: Interleukin-1 and tumor necrosis factor stimulate human vascular endot-helial cells to promote transendothelial neutrophil passage. J Clin Invest 1989, 83:444–455.

    Article  PubMed  CAS  Google Scholar 

  3. US Food and Drug Administration: Etanercept packaging information. http://www.fda.gov/cber/label/ etanimm011502LB.pdf. Accessed March 20, 2003.

  4. US Food and Drug Administration: Adalimumab packaging information. http://www.fda.gov/cber/label/ adalabb123102LB.pdf. Accessed March 20, 2003.

  5. Centecor Incorporated: Infliximab packaging information. http://www.centecor.com/pi/REMPIRA_IN02200_pass5.pdf. Accessed March 20, 2003.

  6. Scallon B, Moore M, Trinh H, et al.: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmem-brane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251–259.

    Article  PubMed  CAS  Google Scholar 

  7. Felson D, Anderson J, Boers M, et al.: The American College of Rheumatology preliminary core set of disease activity mea-sures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993, 36:729–740.

    Article  PubMed  CAS  Google Scholar 

  8. van de Putte L, Atkins C, Malaise M, et al.: Efficacy and safety of adalimumab (D2E7), the first fully human anti-TNF mon-oclonal antibody, in patients with rheumatoid arthritis who failed previous DMARD therapy: 6-month results from a phase III study [abstract]. Ann Rheum Dis 2002, 61(suppl):S168.

    Article  Google Scholar 

  9. van der Heijde D: Plain x-rays in rheumatoid arthritis: over-view of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996, 10:435–453.

    Article  PubMed  Google Scholar 

  10. Rau R, Herborn G, Sander O, et al.: Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radiographic disease progression in rheumatoid arthritis [abstract]. Arthri-tis Rheum 1999, 42(suppl):S400.

    Google Scholar 

  11. Weinblatt M, Keystone E, Furst D, et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal anti-body, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35–45. Phase III study of adalimumab for use in combination with MTX.

    Article  PubMed  CAS  Google Scholar 

  12. Moreland L, Schiff M, Baumgartner S, et al.: Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999, 130:478–486. Phase III study of etanercept in treatment of RA.

    PubMed  CAS  Google Scholar 

  13. Bathon J, Martin R, Fleischmann R, et al.: A comparison of etanercept and methotrexate in patients with early rheuma-toid arthritis. N Engl J Med 2000, 343:1586–1593. Comparison of etanercept with MTX in the treatment of early RA.

    Article  PubMed  CAS  Google Scholar 

  14. Genovese M, Bathon J, Martin R, et al.: Etanercept versus meth-otrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2002, 46:1443–1450.

    Article  PubMed  CAS  Google Scholar 

  15. Weinblatt M, Kremer J, Bankhurst A, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion pro-tein, in patients with rheumatoid arthritis receiving methotr-exate. N Engl J Med 1999, 340:253–259. Study of etanercept in combination with MTX in RA.

    Article  PubMed  CAS  Google Scholar 

  16. Maini R, St. Clair E, Breedveld F, et al.: Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomi-tant methotrexate: a randomized phase III trial. Lancet 1999, 354:1932–1939. Phase III study of infliximab in combination with MTX in treat-ment of RA.

    Article  PubMed  CAS  Google Scholar 

  17. Lipsky P, van der Heijde D, St. Clair E, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594–1602.

    Article  PubMed  CAS  Google Scholar 

  18. Hansen K, Cush J, Patel S, et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthri-tis [abstract]. Arthritis Rheum 2002, 46(suppl):S538.

    Article  CAS  Google Scholar 

  19. Moreland L, Koopman W: Rheumatoid arthritis: anticytokine therapies on the horizon. Ann Intern Med 1998, 128:231–233.

    PubMed  Google Scholar 

  20. Amgen Incorporated: Anakinra packaging information. http:/ /www.amgen.com/news/kineretmedia/support/kineretPI.pdf. Accessed March 20, 2003.

  21. Maini R, Breedveld F, Kalden J, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly meth-otrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552–1563.

    Article  PubMed  CAS  Google Scholar 

  22. Baert F, Noman M, Vermeire S, et al.: Influence of immunoge-nicity on the long-term efficacy of infliximab in Crohn’s dis-ease. N Engl J Med 2003, 348:601–608. Report highlighting the potential role of drug antigenicity in decreased response duration.

    Article  PubMed  CAS  Google Scholar 

  23. US Food and Drug Administration: Clinical review: Abbott bio-logic licensing application STN 125057 adalimumab for use in the treatment of rheumatoid arthritis. Available at http:// www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_01_C-- HUMIRA.Med.Review.pdf. Accessed March 20, 2003.

  24. Schaible T: Treatment of inflammatory diseases: safety of long-term use of infliximab. Presse Med 2001, 30:610–613.

    PubMed  CAS  Google Scholar 

  25. Moreland L, Cohen S, Klareskog L, et al.: Global safety and effi-cacy of more than 5 years of etanercept (ENBREL) therapy in rheumatoid arthritis [abstract]. Arthritis Rheum 2002, 46(suppl):S532.

    Google Scholar 

  26. Kindler V, Sappino A, Grau G, et al.: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56:731–740. Highlights the role of TNF in granulomatous infection.

    Article  PubMed  CAS  Google Scholar 

  27. Mohan V, Scanga C, Yu K, et al.: Effects of tumor necrosis fac-tor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immunol 2001, 69:1847–1855.

    Article  CAS  Google Scholar 

  28. Senaldi G, Yin S: Corynebacterium parvum and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF I receptor (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1996, 157:5022–5026.

    PubMed  CAS  Google Scholar 

  29. Keane J, Gershon S, Wise R, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098–1104. Study highlighting the potential role of TNF inhibition in TB incidence.

    Article  PubMed  CAS  Google Scholar 

  30. US Food and Drug Administration: Briefing document: update on the TNF alpha blocking agents. Available at http:// www.fda.gov/ohrms/dockets/ac/acmenu.htm. Accessed March 20, 2003. An important synopsis of safety issues with the use of TNF antagonists.

  31. Bergstrom L, Yocum D, Tesser J, et al.: Coccidiomycosis (Valley Fever) occurring during infliximab therapy [abstract]. Arthri-tis Rheum 2002, 46(suppl):S169.

    Google Scholar 

  32. Lee J, Slifman N, Gerhon S, et al.: Life-threatening histoplas-mosis complicating immunotherapy with tumor necrosis fac-tor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002, 46:2565–2570.

    Article  PubMed  CAS  Google Scholar 

  33. Slifman N, Gershon S, Lee J, et al.: Listeria monocytogenes infection as a complication of treatment with tumor necro-sis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48:319–324.

    Article  PubMed  CAS  Google Scholar 

  34. Wolfe F: Inflammatory activity, but not methotrexate or pred-nisone use predicts non-Hodgkin’s lymphoma with rheuma-toid arthritis: a 25-year study of 1767 RA patients [abstract]. Arthritis Rheum 1998, 41(suppl):S188.

    Article  Google Scholar 

  35. Baecklund E, Ekbom A, Sparen P, et al.: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998, 517:180–181.

    Google Scholar 

  36. Mohan N, Edwards E, Cupps T, et al.: Demyelination occurring during anti-tumor necrosis factor-a therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862–2869.

    Article  PubMed  CAS  Google Scholar 

  37. Mease P, Ritchlin C, Martin R, et al.: Response to pneumococ-cal vaccination in patients treated with etanercept trial [abstract]. Arthritis Rheum 2001, 44(suppl):S91.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mikuls, T.R., Weaver, A.L. Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep 5, 270–277 (2003). https://doi.org/10.1007/s11926-003-0005-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-003-0005-9

Keywords

Navigation